Phase IB study of TNT009 in patients with Cold Agglutinin Disease

Trial Profile

Phase IB study of TNT009 in patients with Cold Agglutinin Disease

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs TNT 009 (Primary)
  • Indications Autoimmune haemolytic anaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Jun 2017 According to Bioverativ Media Release, True North Therapeutics Has been acquired by Bioverativ
    • 23 May 2017 According to a Bioverativ media release, in May 2017, the FDA granted TNT009 breakthrough therapy designation based on data from this trial.
    • 06 Dec 2016 Results (n=5) assessing pharmacodynamic changes in the complement profile of patients to provide a mechanistic understanding of the hematological responses and therapeutic benefit observed following TNT009 treatment presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top